No Data
No Data
Express News | Oragenics Shares Are Trading Higher After the Company Provided a Corporate Update on Its 2024 Progress Including Developments of ONP-002, Its Lead Candidate for Concussions
Oragenics Shares Are Trading Higher After the Company Provided a Corporate Update on Its 2024 Progress Including Developments of ONP-002, Its Lead Candidate for Concussions.
Express News | Oragenics: In Preparation for Upcoming Phase II Clinical Trials Plans to Submit Australian Regulatory Submission Brochure During Q4
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002
Express News | EXCLUSIVE: Oragenics Tells Benzinga 'Oragenics Is Now Preparing to Move Forward With Human Testing (Phase II) in Patients Who Come to the Emergency Room With a Concussion, Aiming to Give the First Dose of the Drug Within 8 Hours of the Injury'
No Data
No Data